722 related articles for article (PubMed ID: 19883329)
21. 6-oxopurine phosphoribosyltransferase: a target for the development of antimalarial drugs.
de Jersey J; Holý A; Hocková D; Naesens L; Keough DT; Guddat LW
Curr Top Med Chem; 2011; 11(16):2085-102. PubMed ID: 21619515
[TBL] [Abstract][Full Text] [Related]
22. Proteases of malaria parasites: new targets for chemotherapy.
Rosenthal PJ
Emerg Infect Dis; 1998; 4(1):49-57. PubMed ID: 9452398
[TBL] [Abstract][Full Text] [Related]
23. [Malaria: from genetic and molecular biology to disease control].
Ambroise-Thomas P
J Soc Biol; 2004; 198(3):181-5. PubMed ID: 15662933
[TBL] [Abstract][Full Text] [Related]
24. That was then but this is now: malaria research in the time of an eradication agenda.
Kappe SH; Vaughan AM; Boddey JA; Cowman AF
Science; 2010 May; 328(5980):862-6. PubMed ID: 20466924
[TBL] [Abstract][Full Text] [Related]
25. Exploring the flap pocket of the antimalarial target plasmepsin II: the "55 % rule" applied to enzymes.
Zürcher M; Gottschalk T; Meyer S; Bur D; Diederich F
ChemMedChem; 2008 Feb; 3(2):237-40. PubMed ID: 17918177
[No Abstract] [Full Text] [Related]
26. Susceptibility of Plasmodium falciparum to glutamate dehydrogenase inhibitors--a possible new antimalarial target.
Aparicio IM; Marín-Menéndez A; Bell A; Engel PC
Mol Biochem Parasitol; 2010 Aug; 172(2):152-5. PubMed ID: 20399810
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of 9-phosphonoalkyl and 9-phosphonoalkoxyalkyl purines: evaluation of their ability to act as inhibitors of Plasmodium falciparum, Plasmodium vivax and human hypoxanthine-guanine-(xanthine) phosphoribosyltransferases.
Česnek M; Hocková D; Holý A; Dračínský M; Baszczyňski O; Jersey Jd; Keough DT; Guddat LW
Bioorg Med Chem; 2012 Jan; 20(2):1076-89. PubMed ID: 22178188
[TBL] [Abstract][Full Text] [Related]
28. Plasmodium kinases as targets for new-generation antimalarials.
Lucet IS; Tobin A; Drewry D; Wilks AF; Doerig C
Future Med Chem; 2012 Dec; 4(18):2295-310. PubMed ID: 23234552
[TBL] [Abstract][Full Text] [Related]
29. pfcrt is more than the Plasmodium falciparum chloroquine resistance gene: a functional and evolutionary perspective.
Cooper RA; Hartwig CL; Ferdig MT
Acta Trop; 2005 Jun; 94(3):170-80. PubMed ID: 15866507
[TBL] [Abstract][Full Text] [Related]
30. Dietary flavonoids fisetin and myricetin: dual inhibitors of Plasmodium falciparum falcipain-2 and plasmepsin II.
Jin H; Xu Z; Cui K; Zhang T; Lu W; Huang J
Fitoterapia; 2014 Apr; 94():55-61. PubMed ID: 24468190
[TBL] [Abstract][Full Text] [Related]
31. Picomolar Inhibition of Plasmepsin V, an Essential Malaria Protease, Achieved Exploiting the Prime Region.
Gambini L; Rizzi L; Pedretti A; Taglialatela-Scafati O; Carucci M; Pancotti A; Galli C; Read M; Giurisato E; Romeo S; Russo I
PLoS One; 2015; 10(11):e0142509. PubMed ID: 26566224
[TBL] [Abstract][Full Text] [Related]
32. Acyclic phosph(on)ate inhibitors of Plasmodium falciparum hypoxanthine-guanine-xanthine phosphoribosyltransferase.
Clinch K; Crump DR; Evans GB; Hazleton KZ; Mason JM; Schramm VL; Tyler PC
Bioorg Med Chem; 2013 Sep; 21(17):5629-46. PubMed ID: 23810424
[TBL] [Abstract][Full Text] [Related]
33. Novel molecular targets for antimalarial chemotherapy.
Jana S; Paliwal J
Int J Antimicrob Agents; 2007 Jul; 30(1):4-10. PubMed ID: 17339102
[TBL] [Abstract][Full Text] [Related]
34. Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
Keough DT; Skinner-Adams T; Jones MK; Ng AL; Brereton IM; Guddat LW; de Jersey J
J Med Chem; 2006 Dec; 49(25):7479-86. PubMed ID: 17149876
[TBL] [Abstract][Full Text] [Related]
35. Novel molecular targets for antimalarial drug development.
Sahu NK; Sahu S; Kohli DV
Chem Biol Drug Des; 2008 Apr; 71(4):287-97. PubMed ID: 18298458
[TBL] [Abstract][Full Text] [Related]
36. Functional genomics, new tools in malaria research.
Di Girolamo F; Raggi C; Bultrini E; Lanfrancotti A; Silvestrini F; Sargiacomo M; Birago C; Pizzi E; Alano P; Ponzi M
Ann Ist Super Sanita; 2005; 41(4):469-77. PubMed ID: 16569915
[TBL] [Abstract][Full Text] [Related]
37. Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases.
Abdel-Rahman HM; Kimura T; Hidaka K; Kiso A; Nezami A; Freire E; Hayashi Y; Kiso Y
Biol Chem; 2004 Nov; 385(11):1035-9. PubMed ID: 15576323
[TBL] [Abstract][Full Text] [Related]
38. Metabolic enzymes as potential drug targets in Plasmodium falciparum.
Subbayya IN; Ray SS; Balaram P; Balaram H
Indian J Med Res; 1997 Aug; 106():79-94. PubMed ID: 9291679
[TBL] [Abstract][Full Text] [Related]
39. Antimalarial drugs inhibiting hemozoin (beta-hematin) formation: a mechanistic update.
Kumar S; Guha M; Choubey V; Maity P; Bandyopadhyay U
Life Sci; 2007 Feb; 80(9):813-28. PubMed ID: 17157328
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of spiropiperidine hydantoins as a novel class of antimalarial agents.
Meyers MJ; Anderson EJ; McNitt SA; Krenning TM; Singh M; Xu J; Zeng W; Qin L; Xu W; Zhao S; Qin L; Eickhoff CS; Oliva J; Campbell MA; Arnett SD; Prinsen MJ; Griggs DW; Ruminski PG; Goldberg DE; Ding K; Liu X; Tu Z; Tortorella MD; Sverdrup FM; Chen X
Bioorg Med Chem; 2015 Aug; 23(16):5144-50. PubMed ID: 25797165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
